Companies To Watch

Companies To Watch: AltruBio

: AltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.

Companies To Watch: AMO Pharma

AMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.

Companies To Watch: NervGen Pharma

NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.

Companies To Watch: IM Therapeutics

Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.

Companies To Watch: Lyra Therapeutics

Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.

Companies To Watch: Carisma Therapeutics

Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.

Companies To Watch: PhaseBio

PhaseBio is a small, public company aiming to enter a large-market therapeutic area: cardiovascular.

Companies To Watch: Akero Therapeutics

Companies To Watch: Akero Therapeutics - Test-proofing a new metabolism drug to beat the liver disease, NASH

Companies To Watch: Artax Biopharma

Artax Biopharma is challenging the immunosuppressive paradigm with a novel drug for autoimmune diseases.

Companies To Watch: Ridgeback Biotherapeutics

Ridgeback Biotherapeutics is pitting new and potent antivirals versus COVID, Ebola, and other coronaviruses.

Companies To Watch: Osivax

Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.

Companies To Watch: CalciMedica

“In a sense, the Covid association was a golden opportunity for our drug,” says Rachel Leheny, CEO of CalciMedica, a pharma focused on anti-inflammatories for pancreatitis that has now shifted to treatments for Covid-19 pneumonia.

Companies To Watch: Cidara Therapeutics

Cidara Therapeutics is training its novel treatment and preventative for flu and other viral infections on Covid-19.

Companies To Watch: Equillium

Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.